REG - BiVictriX Therapcts. - BiVictriX and Abzena Enter Collaboration

Bivictrix TherapeuticsAnnouncement

18/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211118:nRSR7391Sa&default-theme=true

RNS Number : 7391S  BiVictriX Therapeutics PLC  18 November 2021

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

BiVictriX and Abzena Collaborate to Manufacture Antibody-Drug Conjugates

- BiVictriX has chosen Abzena for cost-effective and timely manufacturing of
its antibody-drug conjugates -

 

Alderley Park and Cambridge, UK - 18 November 2021 BiVictriX Therapeutics plc
(AIM: BVX), an emerging biotechnology company applying a novel approach to
develop next generation cancer therapies using insights derived from frontline
clinical experience is pleased to announce a collaboration to manufacture
BiVictriX's antibody-drug conjugates ("ADC") with Abzena Limited ("Abzena"), a
partner research organisation for integrated discovery to cGMP manufacturing
solutions for biologics.

 

The collaboration will allow BiVictriX to cost-effectively manufacture its
anti-cancer ADCs for use in pre-clinical models without the need for extensive
manufacturing facilities of its own. ADC production will be carried out in two
cycles: the first cycle being ADC manufacturing for proof-of-concept studies;
and the second cycle will cover ADC lead selection and optimisation. This
collaboration has been secured just three months after BiVictriX listed on the
AIM market of the London Stock Exchange, raising gross proceeds of £7.5
million.

 

Tiffany Thorn, Chief Executive of BiVictriX Therapeutics plc, commented:
"Abzena is world-renowned for possessing the expertise and capabilities to
develop and manufacture antibody-drug conjugates to the highest standards.
Utilising Abzena's extensive knowledge in the field will be highly valuable as
we look to expedite the development of our lead candidate, BVX001, and
additional pipeline candidates towards achieving key pre-clinical milestones.
We look forward to this initial collaboration marking the beginning of a
successful and ongoing partnership with Abzena."

Campbell Bunce, Chief Scientific Officer of Abzena, said: "We're delighted to
be able to support the development of BiVictriX's ADCs through our expert
development, characterisation and manufacturing services. BiVictriX's "twin
antigen" targeting Bi-Cygni® therapeutics present an innovative approach to
target cancer cells and we hope to support their development as best we can."

 

**Ends**

 

 

 

   For more information, please contact:

   BiVictriX Contacts:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer               Email: info@bivictrix.com

 Iain Ross, Chairman
                                                     Tel: +44 (0) 20 3470 0470

 SP Angel Corporate Finance LLP (NOMAD and Broker)
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)          Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Ashley Tapp, Suki Virji                             Tel: +44 (0) 20 3709 5700

                           Email: Bivictrix@consilium-comms.com

 

 

 

 

 

  Abzena Contact:

 

 Ramarketing
 Kristy Harmer  Tel: +44 (0)191 222 1242
                Email:   (mailto:%20kristy.harmer@ramarketingpr.com)

kristy.harmer@ramarketingpr.com (mailto:%20kristy.harmer@ramarketingpr.com)

 

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of cancer indications including Diffuse Large
B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic
Cell Neoplasm. The Company is using these novel "twin-antigens" to develop
more effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

 

 

 

About Abzena

Abzena is a leading contract provider of integrated discovery, development and
manufacturing services for biologics and bioconjugates. Abzena provides the
most complete set of solutions in integrated early discovery to mid-phase
biotherapeutic and bioconjugation drug development and manufacturing in the
biopharmaceutical industry. The company maintains resources around the world,
with facilities in the US and UK.

 

Abzena investors include Welsh, Carson, Anderson & Stowe, one of the
world's leading private equity investors, and Biospring Partners
(https://www.biospring.com/). For more information, please see www.abzena.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBRBRTMTBBBLB